Haleon PLC has achieved major milestones in its share buyback program, with multiple rounds completed. Notable sales include GSK unloading its remaining stake in Haleon for $1.5 billion, reducing its stake from 32% to 24%. Pfizer also sought to reduce its stake in the Sensodyne-maker to 24% from 32%. Choreo LLC and Bank of New York Mellon Corp acquired an undisclosed amount of Haleon shares. Meanwhile, Heathbridge Capital Management Ltd. sold 99,500 shares of Haleon. Strategic buybacks have allowed Haleon to consolidate shareholders and regain control of its shares. Its yearly high reached $393.70 which indicates strong market sentiment. Haleon’s financials show promise with a projected high single-digit growth for annual organic operating profit and an 11% growth in first-half results. The company demonstrated innovation with the launch of Eroxon, the first FDA-cleared OTC gel for erectile dysfunction. Haleon is estimated to bring in high returns based on analyst estimates and its strong brand portfolio.
Haleon Stocks News Analytics from Thu, 05 Oct 2023 07:00:00 GMT to Fri, 13 Sep 2024 17:22:27 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -3
